Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Kedudukan dalam Saham
#3625
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Harga Saham
$3.71
Modal Pasaran
$4.69B
Perubahan (1 hari)
2.44%
Perubahan (1 tahun)
-51.92%
Negara
CN
Perdagangan Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Kategori
Healthcare
Nisbah P/B bagi Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Nisbah P/B pada October 2026 TTM: 2.70
Menurut laporan kewangan dan harga saham terkini Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., nisbah P/B semasa (TTM) ialah 2.70. Pada akhir 2023, nisbah P/B syarikat ialah 7.46.
Sejarah nisbah P/B untuk Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. dari 2013 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 2.70 | -64.57% |
| 2024 | 7.63 | 2.35% |
| 2023 | 7.46 | -18.64% |
| 2022 | 9.16 | -63.42% |
| 2021 | 25.05 | -9.41% |
| 2020 | 27.65 | 962.67% |
| 2019 | 2.60 | -10.83% |
| 2018 | 2.92 | -31.74% |
| 2017 | 4.28 | 0.30% |
| 2016 | 4.26 | -22.48% |
| 2015 | 5.50 | -15.25% |
| 2014 | 6.49 | -31.92% |
| 2013 | 9.53 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | 131.26% |
US
|
|
| 13.2547 | 390.37% |
US
|
|
| 4.208 | 55.68% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 128.72% |
NL
|
